| __timestamp | AstraZeneca PLC | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 179279000 |
| Thursday, January 1, 2015 | 4646000000 | 186359000 |
| Friday, January 1, 2016 | 4126000000 | 171785000 |
| Sunday, January 1, 2017 | 4318000000 | 208136000 |
| Monday, January 1, 2018 | 4936000000 | 198405000 |
| Tuesday, January 1, 2019 | 4921000000 | 224169000 |
| Wednesday, January 1, 2020 | 5299000000 | 245044000 |
| Friday, January 1, 2021 | 12437000000 | 252314000 |
| Saturday, January 1, 2022 | 12391000000 | 268225000 |
| Sunday, January 1, 2023 | 8040000000 | 304629000 |
| Monday, January 1, 2024 | 10207000000 | 324203000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, AstraZeneca PLC and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their cost of revenue. AstraZeneca's costs surged by over 100% from 2014 to 2021, peaking in 2021 and 2022, before a notable decline in 2023. In contrast, Taro's costs remained relatively stable, with a modest increase of about 70% over the same period. This disparity highlights AstraZeneca's aggressive expansion and investment strategies, while Taro maintains a more conservative approach. The data for 2024 is incomplete, indicating potential shifts in the coming year. As the pharmaceutical landscape continues to change, these insights provide a glimpse into the strategic decisions shaping the industry's giants.
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
AstraZeneca PLC and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
Analyzing Cost of Revenue: Amgen Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored